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Abstract
Background: DCB-3503, a tylophorine analog, inhibits the growth of PANC-1 (human pancreatic ductal cancer cell line) and
HepG2 (human hepatocellular cancer cell line) tumor xenografts in nude mice. The inhibition of growth leads to cancer cell
differentiation instead of cell death. However, the mechanisms of action of tylophorine analogs is unknown.
Methodology/Principal Findings: In this study, we show that DCB-3503 suppresses the expression of pro-oncogenic or pro-
survival proteins with short half-lives, including cyclin D1, survivin, b-catenin, p53, and p21, without decreasing their mRNA
levels. Proteasome inhibitor reversed the inhibitory effect of DCB-3503 on expression of these proteins. DCB-3503 inhibited
the incorporation of radiolabeled amino acid and thymidine, and to a much lesser degree of uridine, in a panel of cell lines.
The mechanism of inhibition of protein synthesis is different from that of cycloheximide (CHX) as assayed in cell culture and
HeLa in vitro translation system. Furthermore, in contrast to rapamycin, DCB-3503 does not affect protein synthesis through
the mTOR pathway. DCB-3503 treatment shifts the sedimentation profiles of ribosomes and mRNAs towards the polysomal
fractions while diminishing monosome abundance, indicative of the inhibition of the elongation step of protein synthesis.
Preferential down regulation of several studied proteins under these conditions is likely due to the relative short half-lives of
these proteins.
Conclusion/Significance: The inhibitory effect of DCB-3503 on translation is apparently distinct from any of the current
anticancer compounds targeting protein synthesis. Translation inhibitors with novel mechanism could complement current
chemotherapeutic agents for the treatment of human cancers and suppress the occurrence of drug resistance.
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Introduction
Tylophorine analogs are phenanthroindolizidine alkaloids, their
pharmacological actions were first described in 1935 [1]. Studies
from the 1970’s showed that tylocrebrine, tylophorine, and
cryptopelurine inhibit protein synthesis, and inhibit RNA and
DNA synthesis to a lesser extent [2,3]. Since then, tylophorine
analogs have been the subject of numerous investigations due to
their potent antitumor activity [2,4]. Evaluation of (+)-(S)-
tylophorine [DCB-3500 (NSC-717335)] and its analog DCB-
3503 (NSC-716802) (Fig. 1A) in the antitumor screen at the
National Cancer Institute (NCI) showed a fairly consistent and
potent growth inhibitory activity (GI50 ,10
28 M) in all 60 cancer
cell lines, with notable selectivity toward several cell lines, such as
melanoma and lung tumor cell lines [5]. Furthermore, NCI’s
COMPARE program indicated that their activity was unique
among known antitumor compounds, suggesting a mode of action
that is different from current cancer chemotherapeutic compounds
[5]. DCB-3503 has suppressive activity against HepG2 and
PANC-1 tumor xenografts in nude mice [5,6]. It could also
decrease clonogenic activity of HepG2 and PANC-1 cells [5,6,7].
In addition, DCB-3503 is active against chemotherapeutic
resistant KB cell lines overexpressing multidrug resistance
(MDR) and multidrug resistance-associate protein (MRP), and
Topo I down-regulated cells in cell culture [5].
The details of the mechanisms of action of tylophorine analogs
against cancer remain largely unknown [1]. Our previous
structure-activity relationship studies revealed that these analogs
would have the same mechanism of action [8]. The most potent
analog, DCB-3503, had a potent inhibitory effect on NF-kB and
less effect on cyclic AMP response elements (CREs) and activator
protein-1 sites (AP-1)-mediated transcriptions [5]. DCB-3503
could also down-regulate a subset of proteins, including cyclin
D1 [6]. In the present study, we chose several pro-oncogenic and
pro-survival proteins, including cyclin D1, survivin, b-catenin,
p53, and p21 as model proteins to examine the inhibition effects of
DCB-3503 on translation, particularly focusing on cyclin D1.
House keeping gene products like b-actin and tubulin are encoded
by mRNAs with short and unstructured untranslated regions
(UTRs) that are rarely modified. While proto-oncoproteins like
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11607cyclin D1 and pro-survival factors like survivin are encoded by
mRNAs with long and highly structured UTRs that can be
controlled at multiple levels. For example, the expression of cyclin
D1, survivin, and b-catenin can be translationally regulated
through the AU rich elements in the 3’UTR [9]. Cyclin D1
expression can also be controlled by the PI3K/Akt/mTOR/
p70S6K signaling pathways [10]. Understanding the mode of
regulatory effect of DCB-3503 on these proteins could help reveal
the mechanisms of action of tylophorine analogs.
The current study revealed a novel activity of DCB-3503, which
is directed against synthesis of a subset of cell regulatory proteins.
This mode of action is distinct from any other known anticancer
drugs. Based on our current findings and previous reports of the
unique structures, mode of actions, anticancer activities indepen-
dent of MDR-1 and MRP-1, tylophorine analogs have great
potential as a new class of anticancer drugs.
Materials and Methods
Materials
Tylophorine analog DCB-3503 (NSC-716802) was synthesized
in Dr. D. C. Baker’s laboratory (The University of Tennessee,
TN). Cell culture media, fetal bovine serum (FBS) were purchased
from Invitrogen (Carlsbad, CA). All chemicals except otherwise
noted were purchased from Sigma-Aldrich (St. Louis, MO). [
3H]-
amino acid mixture was from GE Healthcare (Arlington Heights,
Figure 1. DCB-3503 down regulated expression of cyclin D1, survivin, b-catenin, p53, and p21. (A) Structure of DCB-3503. (B) and (C)
HepG2 cells and HeLa cells were treated with DCB-3503 for the indicated time and dose. Whole cell lysates were probed with antibodies as indicated.
b-Actin blot was used as internal loading control. D. Down-regulation of cyclin D1 by DCB-3503 in Huh7 and MCF-7 cells. B, C, and D are
representatives from at least three separate experiments. (* Indicating non-specific band).
doi:10.1371/journal.pone.0011607.g001
DCB-3503 Inhibits Translation
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11607IL). [
14C]-thymidine was from Moravek (Brea, CA). [
14C]-uridine
was from MP Biomedicals (Solon, OH). EXPRE
35S
35S protein
labeling mix was from Perkin Elmer (Waltham, MA). Nuclease S7
was from Roche (Indianapolis, IN). Creatine phosphate and MG-
132 were from Calbiochem (Gibbstown, NJ). 19 unlabelled amino
acid mix (lacking L-methionine) was from Promega (Madison,
WI). Rapamycin was from Cell Signaling Technology (Danvers,
MA).
Cell lines and growth conditions
All cell lines were obtained from the American Type Culture
Collection (ATCC). HepG2, Huh7, and MCF-7 cells were
maintained in RPMI 1640 medium supplemented with 10%
FBS. HeLa and PANC-1 cells were maintained in DMEM
containing 4.5 g/l glucose supplemented with 10% FBS. All cell
lines were maintained in a humidified incubator with an
atmosphere of 95% air and 5% CO2 at 37uC.
Western blot analysis
Western blot analysis was done using primary antibodies against
cyclin D1 (Cell Signaling Technology), cyclin E (Santa Cruz
Biotechnology, Santa Cruz, CA), b-catenin (Cell Signaling
Technology), survivin (Cell Signaling Technology), p53 (Santa
Cruz Biotechnology), p21 (Santa Cruz Biotechnology), phospho-
p70 S6 kinase (Thr
389) (Cell Signaling Technology), phospho-S6
ribosomal protein (Ser
235/236) (Cell Signaling Technology), phos-
pho-4E-BP1 (Ser
65) (Cell Signaling Technology), phospho-4E-BP1
(Thr
37/46) (Cell Signaling Technology), 4E-BP1 (Cell Signaling
Technology), and b-actin (Sigma-Aldrich) at optimal dilution.
RNA isolation, real-time PCR and Northern blot analysis
Total cellular RNA was isolated using the RNeasy kit (Qiagen,
Valencia, CA) for real-time PCR and Northern blot analysis.
Poly(A) mRNA was isolated using the Oligotex
TM mRNA kit
(Qiagen). Real-time PCR was performed as previously described
[11] using the following cyclin D1 primer set: 59-AAGCTGTG-
CATCTACACCGA-39, and 59-CTTGAGCTTGTTCACCAG-
GA-39. Probe for cyclin D1 was 59Fam-CCATTTGCAGCAGC-
TCCTCGG-39Tamra. The primer pairs and Taqman probes for
survivin, b-catenin, p53, p21, and b-actin have been published
previously [11,12,13]. Eight microgram total RNA was separated
ondenaturedagarosegeland transferredtoHybondN
+membrane.
Northern blot analysis was performed using a random primer
labeled [
32P] cyclin D1 probe.
[
3H]-amino acid mixture incorporation assay
HepG2, HeLa, and PANC-1 cells labeled with [
3H]-amino acid
mixture were either treated with DCB-3503 or CHX, or left
untreated as control. The incorporation of [
3H]-amino acid into
TCA-insoluble cellular components of each treatment was
quantified using Beckman scintillation counter (Beckman Instru-
ments, Fullerton, CA).
[
35S]-amino acid mixture incorporation assay
HepG2 cells were labeled with 50 mCi/ml [
35S]-methionine/
cysteine for 30 minutes before harvest. Incorporation of [
35S]-
methionine/cysteine was determined either by SDS-PAGE for
protein profiling or by immunoprecipitation with cyclin D1
antibody.
[
14C]-thymidine and [
14C]-uridine incorporation assay
HepG2 and PANC-1 cells labeled with [
14C]-thymidine or
[
14C]-uridine were either treated with DCB-3503, CHX, hy-
droxyurea, actinomycin D, or left untreated as control [8]. The
incorporation of [
14C]-thymidine or [
14C]-uridine into TCA-
insoluble cellular components of each treatment was quantified
using Beckman scintillation counter.
In vitro transcription assay
Phagemid Bluescript SK- containing the cyclin D1 coding
region was linerized by Hind III, and was used as the template for
in vitro transcription. Uncapped Cyclin D1 mRNA was generated
by MEGAscript kit containing T7 RNA polymerase (Ambion,
Austin, TX). Capped cyclin D1 mRNA was generated by using a
mMESSAGE mMACHINE high yield capped RNA transcription
kit containing T7 RNA polymerase (Ambion). Polyadenylated
cyclin D1 mRNA was generated by using a poly(A) tailing kit
(Ambion). Luciferase encoding plasmids T3 luc and T3 luc (A)
(poly A tail of 98 adenosines) were linearized by BamHI, and were
used as the template for the following in vitro transcription.
Uncapped luciferase mRNA with poly(A) tail was generated by
MEGAscript kit containing T3 RNA polymerase (Ambion).
Capped luciferase mRNA with and without poly(A) tail was
generated by mMESSAGE mMACHINE high yield capped RNA
transcription kit containing T3 RNA polymerase (Ambion). All the
in vitro transcribed mRNAs were purified by MEGAclear kit
(Ambion). The integrity of all the in vitro transcribed mRNAs was
confirmed by denatured agarose gel electrophoresis. The purified
mRNAs were used for in vitro translation experiments.
In vitro translation using HeLa cell free system
The procedure for the extraction of HeLa cytosolic extracts for
in vitro translation has been described previously [14]. The in vitro
translation mixtures containing 50 ng/ml cyclin D1 mRNA were
incubated at 30uC for 90 minutes. Translation products of cyclin
D1, T3 luc, and T3 luc(A) mRNAs were resolved by SDS-PAGE
followed by autoradiography, or luciferase assay, respectively.
Luciferase assay
Luciferase activity wasmeasured by luciferase assay kit (Promega)
according to the manufacturer’s instructions.
Polysome profile analysis
Polysome profile analysis was performed essentially as described
previously [15]. In brief, cytoplasmic extracts from control or drug
treated cells were overlayed on the 10–50% sucrose gradients and
centrifuged at 39,000 rpm for 80 minutes at 4uC using a SW 41Ti
Beckman Coulter rotor (Beckman Coulter, Brea, CA). Fractions
were collected with a continuous autodensi-flow density gradient
fractionator (Labconco, Kansas City, MO). Total RNA from each
fraction was isolated by Trizol (Invitrogen) method. Amount of
specific mRNAs in each fraction was analyzed by real-time PCR.
Results
DCB-3503 suppresses the expression of a subset of
proteins
The expression of cylcin D1, survivin, b-catenin, p53, and p21
were down-regulated by DCB-3503 in a time- and dose-dependent
manner in HepG2 cells using Western blot analysis (Fig. 1B). In
contrast, the expression of cyclin E and b-actin did not
significantly change under the same conditions. Cyclin D1 was
down-regulated as early as 15 minutes after treatment with
300 nM DCB-3503 (Fig. 1B left panel, compare Lane 2 and Lane
1), and its expression was suppressed extensively by as low as
50 nM DCB-3503 treatment for 2 hours (Fig. 1B right panel,
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regulation of cyclin D1, survivin, and b-catenin in the same
fashion in HeLa cells (Fig. 1C). The down-regulatory effect of
DCB-3503 on p53 and p21 in HeLa cells was difficult to evaluate
due to the low endogenous level of these proteins (data not shown).
The time- and dose-dependent suppression of cyclin D1 induced
by DCB-3503 treatment was also observed in Huh7 and MCF-7
cells (Fig. 1D). Therefore, the down-regulatory effect of DCB-3503
on proto-oncoprotein cyclin D1 is not cell type-specific. This is in
agreement with our previous findings that DCB-3503 down-
regulated cyclin D1 in HepG2, and PANC-1 cells [6,7].
DCB-3503 does not decrease mRNA levels of the
suppressed proteins
To analyze the underlying mechanism of DCB-3503 suppressed
protein expression, we first assessed whether DCB-3503 could
affect mRNA levels of these proteins using real-time PCR analysis.
DCB-3503 caused a steady increase to about 2 fold in mRNA
levels of cyclin D1 and p53 during the first 8-hour of treatment
and then tapered off to the untreated control level by 24 hours
(Fig. 2A). DCB-3503 exhibited little effect on mRNA levels of
survivin, b-catenin, and p21 through out the treatment (Fig. 2A).
The increase in mRNA level could be due to the compensatory
regulation of cyclin D1 and p53 proteins. In contrast, CHX
significantly increased mRNA levels of cyclin D1 and p21 after
24 hours treatment, but did not alter mRNA levels of other
proteins studied (Fig. 2A). Northern blot analysis revealed that
cyclin D1 mRNA level was increased by DCB-3503 after 2-hour
treatment (Fig. 2B). The 4.8 kb and 1.7 kb RNA transcripts of
cyclin D1, which have the same coding sequence but differ in
polyadenylation [16], remained unchanged after treatment with
DCB-3503. Thus, DCB-3503 suppression of protein accumulation
cannot be due to the decrease of mRNA levels. However, we
cannot rule out the possibility that the unchanged transcripts of
cyclin D1 mRNA are due to the compensation of the inhibitory
effect of DCB-3503 on cyclin D1 expression.
DCB-3503 dose not increase the degradation of proteins
with short half-lives
We next examined whether DCB-3503 treatment could induce
degradation of cyclin D1, survivin, b-catenin, p53, and p21. CHX
blocks peptidyl transferase activity in eukaryotic ribosomes, and it
was used to stop protein synthesis in eukaryotic cells for the
estimation of the half-life. We found that the half-life of cyclin D1
in HepG2 cells is relatively short (,0.5 hour) as compared to that
of b-actin (.4 hours, Fig. 2C, right panel). The half-lives of other
proteins in the presence of CHX was determined to be in the
order of survivin $b-catenin . p53 . cyclin D1 $ p21. We next
assessed whether the combined treatment of CHX and DCB-3503
could enhance the suppression of the cell regulatory proteins we
examined, compared to CHX treatment alone. The intensities of
the bands of these proteins were quantified using a densitometer,
and normalized to that of b-actin and marked below each band
(Fig. 2C). When CHX was present, there was no detectable
difference in the kinetics of decay of cyclin D1, survivin, b-catenin,
p53, and p21 in the presence or absence of DCB-3503 (Fig. 2C).
Pre-exposure of HepG2 cells to 2 mM MG-132, a proteasome
inhibitor, following the addition of DCB-3503 reversed the
suppression of cyclin D1, survivin, b-catenin, p53, and p21 by
DCB-3503 treatment within 4 hours (Fig. 2D a). However, MG-
132 at 2 mM cannot abolish the cytotoxicity of DCB-3503 after
24-hour treatment (Fig. 2D b). Higher concentration of MG-132
(10 mM) caused cell death in the presence or absence of DCB-3503
with overnight culture (data not shown). Taken together, these
results indicate that DCB-3503 does not increase the rate of
degradation of this subset of proteins.
DCB-3503 inhibits amino acid incorporation in a time-
and dose-dependent manner
The above results indicated that DCB-3503 suppresses cell
regulatory proteins at the translational level. We therefore
measured global changes of protein synthesis in response to
DCB-3503 treatment. A time course of [
3H]-amino acid
incorporation into proteins is affected by DCB-3503 as shown in
Fig. 3A. At 100 nM, DCB-3503 inhibited [
3H]-amino acid
incorporation as early as by 15 minutes of treatment (Fig. 3A a).
This inhibition was DCB-3503 dose-dependent but not cell type
specific, as observed in HeLa (Fig. 3B a) and PANC-1 cells (Fig. 3B
b). DCB-3503 treatment inhibited [
3H]-amino acid incorporation
by 50% at 100 nM, whereas 100 mg/ml of CHX totally blocked it
(Fig. 3A a). This could imply an enhanced susceptibility to DCB-
3503 mediated inhibition for a subset of proteins. In addition,
suppression of global protein synthesis by DCB-3503 was revealed
by [
35S]-methionine/cysteine incorporation assay in HepG2 cells
(Fig. 3C, left panel). The amount of newly synthesized cyclin D1
protein in DCB-3503 treated HepG2 cells was assessed by
immunoprecipitation with an anti-cyclin D1 antibody of [
35S]-
labeled proteins. There was a reduction in the amount of
radioactivity in a major immunoprecipitable polypeptide that
corresponds to cyclin D1 at 300 nM as established by immuno-
blotting (Fig. 3C, right panels). DCB-3503 inhibited cyclin D1 and
total protein synthesis with similar efficiency as indicated by the
quantitative analysis of [
35S] incorporation (Fig. S1E). These
results indicate that DCB-3503 inhibits global protein synthesis,
which has preferential effect on proteins with short half-life, like
cyclin D1.
DCB-3503 preferentially inhibits [
14C]-thymidine
incorporation, but not [
14C]-uridine incorporation, in a
time- and dose-dependent manner
In addition to protein synthesis, nucleic acid synthesis is
inhibited by tylocrebrine [17]. We investigated DNA and RNA
synthesis by monitoring [
14C]-thymidine and [
14C]-uridine
incorporation in HepG2 cells. Time course studies indicated that
300 nM DCB-3503 began to show inhibitory effect on [
14C]-
thymidine incorporation into DNA within 30 minutes of treatment
(Fig. 4A). In addition, there was dose-dependent down-regulation
of [
14C]-thymidine incorporation into DNA by DCB-3503
treatment in both PANC-1 and HepG2 cells (Fig. 4B and
supplemental Fig. S1). DCB-3503 caused less than 50% inhibitory
effect on [
14C]-uridine incorporation into RNA at 300 nM after 2-
hour treatment (Fig. 4C and D). Increasing concentrations of
DCB-3503 beyond 300 nM did not further exaggerate the
inhibition of [
14C]-uridine incorporation (Fig. 4D). CHX did not
show inhibitory effect on [
14C]-uridine incorporation under the
same conditions (Fig. 4C). Similar results were obtained in PANC-
1 cells (Supplemental Fig. S1).
DCB-3503 inhibits translation of cyclin D1 mRNA in HeLa
cell extracts at high concentrations
Since DCB-3503 treatment inhibited incorporation of amino
acid and cyclin D1 synthesis in cell culture, we investigated
whether DCB-3503 treatment could inhibit translation of cyclin
D1 mRNA in vitro. Attempts to set up in vitro translation system
using PANC-1 cells (referred to originally established methods
with HeLa [18,19]) and HepG2 cells (methods adapted as
DCB-3503 Inhibits Translation
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were not successful. We therefore established HeLa cell extract in
vitro translation system [14]. This system was reported to
recapitulate synergistic stimulation of translation by the terminal
mRNA structures, the 39 poly(A) tail and the 59 cap [14].
Consistent with previous report, capped polyadenylated cyclin D1
mRNA had significantly higher translation efficiency in compar-
ison to that of uncapped non-polyadenylated cyclin D1 mRNA
(Fig. 5A, compare lane 6 to lane 2). Three hundred nanomoles of
DCB-3503 inhibited less than 50% of translation of either
uncapped (Fig. 5A, compare lane 3 to lane 2) or capped cyclin
D1 mRNA compared to untreated control level (Fig. 5A, compare
lane 7 and lane 6). However, 1 mM of DCB-3503 treatment
markedly inhibited translation of both uncapped and capped
cyclin D1 mRNA (Fig. 5A, compare lane 4 to lane 2, and lane 8 to
lane 6). By comparison, CHX completely blocked both capped
Figure 2. DCB-3503 did not decrease mRNA levels of cyclin D1, survivin, b-catenin, p53, and p21. A. HepG2 cells were treated with either
DCB-3503 or CHX for the indicated time. mRNA levels of cyclin D1, survivin, b-catenin, p53, and p21 were analyzed by real-time RT-PCR using specific
primers and probes and were normalized to that of b-actin. Values are depicted as mean 6 S.D. from at least three separate experiments and are
expressed relative to the basal mRNA level in the corresponding untreated control cells. B. mRNA level of cyclin D1 was analyzed by Northern blot
under DCB-3503 treatment. Ribosomal RNA gel image on the bottom panel shows equal loading of total RNA. C. Expressions of cyclin D1, survivin, b-
catenin, p53, and p21 under treatment of CHX, DCB-3503, and CHX and DCB-3503 in combination were examined by Western blot analysis in HepG2
cells. b-Actin blot was used as internal loading control. D. (a)2mM MG-132 reverses suppression of cyclin D1, survivin, b-catenin, p53, and p21 by
DCB-3503 within 4-hour culture, (b)2mM MG-132 does not block cytotoxicity of DCB-3503 after 24-hour treatment. B, C, and D are representatives
from at least three separate experiments. Numbers marked in C are normalized band intensity. (* Indicating non-specific band).
doi:10.1371/journal.pone.0011607.g002
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compare lane 5 to lane 2, and lane 9 to lane 6). Similar results
were obtained using T3 luciferase mRNA as a model (discussed
below).
DCB-3503 acts differently from CHX and rapamycin
Translation efficiency is positively regulated by the 59 cap
structure and the 39 poly(A) tail. We therefore used capped
luciferase mRNA with or without poly(A) tail to program HeLa
cell-free extracts. The addition of 1 mM DCB-3503 produced
about 50% inhibitory effect on translation of both non-
polyadenylated and polyadenylated luciferase mRNAs (Fig. 5B).
CHX completely blocked translation of T3 luciferase mRNA in
vitro. The mTOR inhibitor, rapamycin, had no inhibitory effect on
translation of either type of mRNA under the same conditions.
Western blot results showed DCB-3503 elevated phosphorylations
of p70 S6 kinase, 4E-BP1 at Ser
65 and Thr
37/46 sites, and had no
effect on phosphorylation of S6 ribosomal after 2-hour treatment
in HepG2 cells (Fig. 5C). In contrast, rapamycin completely
inhibited phosphorylation of p70 S6 kinase (Thr
389) and reduced
Figure 3. DCB-3503 inhibited incorporation of amino acid in a time- and dose-dependent manner. A. DCB-3503 inhibited [
3H]-amino
acid incorporation in both time- (a) and dose-dependent (b) manner in HepG2 cells. B. DCB-3503 inhibited [
3H]-amino acid incorporation in HeLa
cells (a) and PANC-1 cells (b) in a dose-dependent fashion. A and B results from three separate experiments are presented as mean 6 S.D. C.
Inhibitory effect of DCB-3503 on global protein synthesis and cyclin D1 protein synthesis assessed by [
35S]-methionine/cysteine incorporation. This is
a representative from three separate experiments.
doi:10.1371/journal.pone.0011607.g003
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235/236) level to about
50% of untreated control under the same condition (Fig. 5C).
Rapamycin only suppressed phosphorylation of 4E-BP1 at Ser
65,
which can inhibit cap-dependent translation downstream of
mTOR by inhibiting the rate-limiting translational initiator eIF4E
[22,23,24]. These results indicate that the action of DCB-3503 is
different from that of CHX and rapamycin.
DCB-3503 induces changes in polysome profile and
mRNA distribution
To further characterize the effects of DCB-3503 on translation,
we compared polysome profiles of DCB-3503 or CHX-treated
HepG2 and HeLa cells to untreated control cells. DCB-3503
increased the abundance of polysomes at the expense of
monosomes, with heavy polysomes being relatively more affected
than light polysomes (Fig. 6A). Such an effect on the polysome
profile is a hallmark of inhibition of elongation [25]. CHX
treatment stabilized polysomes in both HepG2 and HeLa cells
(Fig. 6A). We then analyzed distribution of mRNAs of cyclin D1,
survivin, b-catenin, and b-actin in the sucrose gradient fractions
from HepG2 cells using real-time PCR. DCB-3503 induced
sedimentation shift of all these mRNAs to the non-translation
proficient polysome fractions of the gradient in a time- and dose-
dependent manner (Fig. 6B and Fig. S2). The increased
accumulation of cyclin D1, survivin, b-catenin, and b-actin
mRNAs in the polysome fractions is consistent with the inhibition
of the elongation step of translation by DCB-3503. This result is in
line with previous report that tylophorine analogs prevent break
down of polysomes in Saccharomyces cerevisiae [3].
Discussion
This study demonstrates that cyclin D1 protein could be down-
regulated as early as 15 minutes after DCB-3503 treatment (Fig. 1).
In contrast, availability of cyclin D1 mRNA remain unchanged
under similar condition (Fig. 2A and B). We also found that DCB-
3503 treatment suppressed the expression of cyclin D1, survivin, b-
catenin, p53, and p21. Combined treatment of DCB-3503 and
Figure 4. DCB-3503 preferentially inhibited [
14C]-thymidine incorporation in a time- and dose-dependent manner, but not [
14C]-
uridine incorporation. A. and B. The inhibitory effect of DCB-3503 on [
14C]-thymidine incorporation was time-dependent and dose-dependent in
HepG2 cells. (C) and (D) DCB-3503 showed less than 50% inhibition on [
14C]-uridine incorporation in either HepG2 cells followed by different time
and dose treatment. Hydroxyurea (Hu) and actinomycin D were used as positive controls. Values are depicted as mean 6 S.D. from at least three
separate experiments.
doi:10.1371/journal.pone.0011607.g004
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compared to the treatment with CHX alone (Fig. 2C).Treatment of
DCB-3503 inhibited the incorporation of [
3H]- or [
35S]-amino acid
into proteins as measured in HepG2, HeLa, and PANC-1 cells in a
time- and dose-dependent manner (Fig. 3).In addition, we observed
that DCB-3503 preferentially suppressed the rate of [
14C]-
thymidine incorporation into DNA (Fig. 4A), but this could be a
secondaryevent followingthedown-regulationofa subsetofcellular
proteins involved in DNA synthesis. Xi et al reported an alternative
possibility that tylophorine analogs can interact with bulged DNA
directly, and then interfere with DNA synthesis [26]. However, we
were unable to demonstrate that DCB-3503 interacts with DNA
using ethidium displacement analysis (data not shown).
A variety of antitumor agents suppress transcription and/or
translation of cyclin D1; these include retinoic acid, rapamycin,
LY294002, wortmannin, herbimycin A, and geldanamycin
[27,28]. Additionally, inhibitors of translational elongation like
homoharringtonine, bruceantin, and didemnin B, can also inhibit
expression of cyclin D1 [29]. These compounds down-regulate
cyclin D1 expression through different mechanisms. Retinoic acid
induces proteasomal degradation of cyclin D1 and exhibits no
effect on cyclin D1 mRNA level. GSK3 plays a key role in retinoid
regulation of cyclin D1 [28]. Rapamycin, a well-known mTOR
inhibitor, suppresses initiation of cyclin D1 mRNA translation
through inhibition of the mTOR-ribosomal p70 S6 kinase and
mTOR-eukaryotic initiation factor 4E-binding protein-1 (eIF4E)
pathways. In addition, rapamycin-stimulated activation of GSK3b
leads to a decrease in the half-life of cyclin D1 and induction of
cyclin D1 proteolysis [27]. Differential inhibition of cyclin D1
expression by PI3K inhibitors, LY294002, and wortmannin, is
Figure 5. DCB-3503-mediated inhibition of protein synthesis differs from that of CHX and rapamycin. A. Effects of DCB-3503 and CHX
on translation of uncapped and capped poly(A) tail cyclin D1 mRNAs in HeLa cell free lysate system. B. Effects of DCB-3503, CHX, and rapamycin on
translation of capped luciferase mRNAs with or without 3’poly(A) tail in HeLa cell free lysate system. Values are depicted as mean 6 S.D. from at least
three separate experiments. C. Western blot analysis of phosphorylated p70 S6Kinase T
389,S 6S
235/236, phosphorylated 4EBP1 S
65 and T
37/46 under
DCB-3503 and rapamycin treatment for 2 hours in HepG2 cells. 4EBP1 and b-Actin blots were used as internal loading controls. A and C are
representatives from three separate experiments.
doi:10.1371/journal.pone.0011607.g005
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Herbimycin A, a potent tyrosine kinase inhibitor, down-regulates
cyclin D1 protein by suppressing synthesis of its mRNA [31].
Geldanamycin, a potent heat shock protein 90 (HSP90) inhibitor,
can induce cyclin D1 down-regulation through suppression of
mTOR signaling pathway by disrupting the in vivo binding of
HSP90 with mTOR raptor [32]. Homoharringtonine and
bruceantin inhibit polysome chain elongation on poly(U)-pro-
grammed 80S ribosomes, as assayed by polysome profiling
[33,34]. Didemnin B suppressed translation through binding to
the eukaryotic elongation factor 1a in GTP-dependent manner
[35]. The action of DCB-3503 on inhibition of protein translation
is distinct from that of the above-mentioned compounds, and is
apparently operating at the elongation phase of translation (Fig. 6).
Huang et al reported that 100 mM of tylocrebrine inhibited
protein synthesis during chain elongation [17]; Grant et al
reported that 130 mM of cryptopeurine inhibited protein synthesis
in the translocation phase [36]. These concentrations were far
above the relevant concentration we studied (100 nM, 300 nM or
maximum 1 mM, Fig. 5 and 6). The structures of the above two
tylophorine analogs are different from DCB-3503. These structure
analogs of tylophorine may not be functional analogs, as we
demonstrated previously [8]. The high cytotoxicity of DCB-3503
may also be due to its inhibition of elongation phase in translation
(Fig. 6). Translation elongation inhibitors can sensitize chemo-
therapeutic agents [29,37,38]. Additionally, inhibition on transla-
tion elongation can overcome drug resistance [39,40]. One
possibility is that the proto-oncoproteins and pro-survival factors
exhibit higher translation rates in cancer cells, and inhibition of all
mRNAs elongation will turn out to have more profound effect on
mRNAs of these proteins [41]. Alternatively, proto-oncoproteins
and pro-survival factors have relatively short half-lives, and are
more likely to be depleted by inhibition of elongation [29,42].
We observed partial inhibitory effect on translation with 1 mM
DCB-3503 in Hela cell extracts system (Fig. 5A), which is less
effective dosage on cell based studies (Fig. 1). Intracellular
regulators that control elongation may be only partially operative
in in vitro translation systems [43]. Such factors can be elongation
factors, or recently actively studied miRNAs. Phosphorylation
status of initiation factors and components of signaling pathways
may vary in in vitro systems and in intact cells. In cell free systems,
eukaryotic translation initiation factor 2a (eIF2a) and eIF2a
kinases, and many other kinases become phosphorylated due to
the presence of essential supplements, such as ATP and creatine
phosphate [44]. Phosphorylation of eIF2a may introduce a new
limiting step in the translation process at the level of initiation [45].
Thus, DCB-3503-induced decrease in the rate of polypeptide
chain elongation may not be fully reflected in the rate of protein
synthesis in vitro, in contrast to the situation in vivo. miRNAs are
small noncoding RNAs that regulate the stability and/or
translation of mRNAs [46]. Preliminary studies of miRNA
profiling showed that DCB-3503 altered the homeostasis of a
number of miRNAs after 4-hour treatment (unpublished data).
The possibility that the regulated miRNA homeostasis is a cause or
consequence of inhibition of protein synthesis is currently under
investigation.
In summary, our results indicate that DCB-3503 inhibits
protein synthesis by reducing the rate of polypeptide chain
elongation. The global inhibition effect on protein synthesis,
however, could be expected to suppress proteins with a shorter
half-life more profoundly than proteins with a longer half-life. The
immediate and rapid changes of these proteins regulated by
translation are important in physiological conditions like apoptosis
and cellular stress. Such proteins could include cyclin D1 or co-
activators regulating NF-kB mediated transcription. The half-lives
and the roles of these proteins down-regulated by DCB-3503 in
different cells or tissues could be different. Long-term suppression
of protein synthesis could lose the selectivity. This can explain why
DCB-3503 has therapeutic activity against cancer cell growth,
lupus, and arthritis in mice when it is given every three days, as we
reported previously [5,6,47,48]. Therapeutic index of DCB-3503
against cancer cells in vivo may be lost when it is given daily. The
effectiveness of this class of analogs for the treatment of disease will
be highly schedule-dependent. The mechanism of inhibition of
protein synthesis by DCB-3503 is likely to be distinct from the
known inhibitors of protein synthesis. Unraveling this mechanism
may open a window for new therapeutic opportunities for the
treatment of human cancers, including hepatocellular carcinoma.
DCB-3503 may be used in combination treatment of malignant
cancers with therapeutic agents that show different mechanisms of
Figure 6. DCB-3503 inhibited the elongation step of translation. A. DCB-3503 treatment induced accumulation of polysomes in HepG2 and
HeLa cells after 1-hour treatment. B. DCB-3503 induced accumulation of mRNAs of cyclin D1 and b-Actin in polysomal fractions in the sucrose
gradient in HepG2 cells. A and B were representatives from three separate experiments with similar results.
doi:10.1371/journal.pone.0011607.g006
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phenotypes characterized by MDR-1 and MRP-1 overexpression.
Supporting Information
Figure S1 DCB-3503 inhibited [14C]-thymidine incorporation
in a time- and dose-dependent manner, but not [14C]-uridine
incorporation in PANC-1 cells. The inhibitory effect of DCB-3503
on [14C]-thymidine incorporation was time-dependent (A) and
dose-dependent (B) in PANC-1 cells. DCB-3503 showed less than
50% inhibition on [14C]-uridine incorporation in either PANC-1
cells followed by different time (C) or dose treatment (D). E.
Normalized relative incorporation of [35S]-methionine/cysteine
into total protein and cyclin D1 presented in Figure 3C through
three separate experiments and presented as mean 6 S.D.
Found at: doi:10.1371/journal.pone.0011607.s001 (6.23 MB
TIF)
Figure S2 Effects of DCB-3503 on mRNA distribution of cyclin
D1, survivin, b-catenin, and b-actin in fractions HepG2 cells
obtained from sucrose gradient were quantitated by real-time RT
PCR.
Found at: doi:10.1371/journal.pone.0011607.s002 (6.43 MB
TIF)
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